MedTrace Logo

Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.

NCT06376773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 234

Last updated 2024-04-19

No results posted yet for this study

Summary

Extensive research employing diverse omics methodologies has unveiled a varied landscape of gastric cancer (GC). Recent progress in next-generation sequencing and other genomic technologies has facilitated a more intricate exploration of GC at the molecular level. This study aimed to identify the most effective drug therapeutics for patients with the mesenchymal subtype of gastric cancer.Based on RNA-seq transcriptome, 234 patients were divided into four molecular subtypes: mesenchymal, immunogenic, metabolic, and classic.Our analysis has revealed that, for neoadjuvant therapy in advanced gastric cancer (AGC), the mesenchymal subtype stands out as the ideal patient population benefiting from Apatinib, without a concurrent increase in postoperative complications.

Conditions

  • Advanced Gastric Cancer
  • Neoadjuvant Therapy
  • Multi-omics Analysis

Interventions

PROCEDURE

combination chemotherapy with Apatinib or Camrelizumab

Apatinib, chemotherapy alone, Camrelizumab

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-07-01
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06376773 on ClinicalTrials.gov